Fig. 1
From: Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer
Experimental design. Workflow with multiple steps: A cohort of sq-BLCA samples (n = 114) already characterised for therapeutic targets in previous studies (sample numbers varies for targets; *(20, 23, 24)) was immunohistochemically stained and assessed for immune cell markers. TMA slide images were annotated for stromal and tumour areas and immune cells were automatically quantified to determine immune cell densities. Resulting immune phenotypes were correlated with therapeutic targets (or expression of marker molecules). Black scale bar (left panel): 50 µM; Black scale bar (right panel): 250 µM